BACKGROUND: Initiation of efavirenz is commonly associated with sleep disturbances. Assessment of sleep using the electroencephalogram and electromyogram enables sleep staging to be performed and changes following the introduction of therapy to be evaluated. METHODOLOGY: Using standardized sleep-staging methodology, we investigated sleep staging and sleep quality by patient self-report in an open-label cohort pilot study. Assessments were performed prior to the initiation of efavirenz, 2 weeks after the initiation of efavirenz and 3 months after the initiation of efavirenz. The study included HIV-positive individuals without central neurological disease who were naive to antiretroviral treatment. All patients initiated treatment with two nucleoside reverse transcriptase inhibitors in combination with efavirenz. RESULTS: Ten patients completed all three study visits. Patients reported an increase in recollection of dreams and morning sluggishness after the initiation of efavirenz which persisted for 3 months. Sleep-staging data indicated a modest reduction in stage 2 sleep with a corresponding increase in deep sleep stage 4 and a modest increase in rapid eye movement (REM) sleep. Overall sleep maintenance efficiency did not significantly change from baseline. Changes in sleep staging were most marked 2 weeks after the initiation of efavirenz but remained different from baseline patterns at 3 months. CONCLUSION: The data indicate that efavirenz has a modest but persistent impact on the time spent in several key sleep stages. Patients reported persistence of dream recollection but remained satisfied with sleep quality and overall quality of life.
BACKGROUND: Initiation of efavirenz is commonly associated with sleep disturbances. Assessment of sleep using the electroencephalogram and electromyogram enables sleep staging to be performed and changes following the introduction of therapy to be evaluated. METHODOLOGY: Using standardized sleep-staging methodology, we investigated sleep staging and sleep quality by patient self-report in an open-label cohort pilot study. Assessments were performed prior to the initiation of efavirenz, 2 weeks after the initiation of efavirenz and 3 months after the initiation of efavirenz. The study included HIV-positive individuals without central neurological disease who were naive to antiretroviral treatment. All patients initiated treatment with two nucleoside reverse transcriptase inhibitors in combination with efavirenz. RESULTS: Ten patients completed all three study visits. Patients reported an increase in recollection of dreams and morning sluggishness after the initiation of efavirenz which persisted for 3 months. Sleep-staging data indicated a modest reduction in stage 2 sleep with a corresponding increase in deep sleep stage 4 and a modest increase in rapid eye movement (REM) sleep. Overall sleep maintenance efficiency did not significantly change from baseline. Changes in sleep staging were most marked 2 weeks after the initiation of efavirenz but remained different from baseline patterns at 3 months. CONCLUSION: The data indicate that efavirenz has a modest but persistent impact on the time spent in several key sleep stages. Patients reported persistence of dream recollection but remained satisfied with sleep quality and overall quality of life.
Authors: Girardin Jean-Louis; Kathleen M Weber; Bradley E Aouizerat; Alexandra M Levine; Pauline M Maki; Chenglong Liu; Kathryn M Anastos; Joel Milam; Keri N Althoff; Tracey E Wilson Journal: Sleep Date: 2012-01-01 Impact factor: 5.849
Authors: Charlene E Gamaldo; Adam P Spira; Rebecca S Hock; Rachel E Salas; Justin C McArthur; Paula M David; Gilbert Mbeo; Michael T Smith Journal: AIDS Behav Date: 2013-10
Authors: Cecilia M Shikuma; Lindsay Kohorn; Robert Paul; Dominic C Chow; Kalpana J Kallianpur; Maegen Walker; Scott Souza; Louie Mar A Gangcuangco; Beau K Nakamoto; Francis D Pien; Timothy Duerler; Linda Castro; Lorna Nagamine; Bruce Soll Journal: HIV Clin Trials Date: 2018-11-19
Authors: Kristin M Gunnarsdottir; Yu Min Kang; Matthew S D Kerr; Sridevi V Sarma; Joshua Ewen; Richard Allen; Charlene Gamaldo; Rachel M E Salas Journal: Conf Proc IEEE Eng Med Biol Soc Date: 2015
Authors: Yu Min Kang; Kristin M Gunnarsdottir; Matthew S D Kerr; Rachel M E Salas; Joshua Ewen; Richard Allen; Charlene Gamaldo; Sridevi V Sarma Journal: Conf Proc IEEE Eng Med Biol Soc Date: 2015
Authors: Charlene E Gamaldo; Alyssa Gamaldo; Jason Creighton; Rachel E Salas; Ola A Selnes; Paula M David; Gilbert Mbeo; Benjamin S Parker; Amanda Brown; Justin C McArthur; Michael T Smith Journal: J Acquir Immune Defic Syndr Date: 2013-08-15 Impact factor: 3.731
Authors: Hilda Azimi; Kristin M Gunnarsdottir; Sridevi V Sarma; Alyssa A Gamaldo; Rachel M E Salas; Charlene E Gamaldo Journal: Annu Int Conf IEEE Eng Med Biol Soc Date: 2020-07